Abstract
Pentostatin (Nipent; SuperGen, San Ramon, CA), which is highly lymphocytotoxic, is an active agent in hairy cell leukemia. We therefore initiated a trial of this agent in T-cell lymphomas. Pentostatin was administered at a dose of 3.75 or 5.0 mg/m2/d intravenously for 3 days every 3 weeks to heavily pretreated patients with cutaneous and peripheral T-cell lymphomas. To date, there are 24 evaluable patients in the trial. Seventeen of these individuals have responded (complete or partial remission). The most common toxicities included granulocytopenia, nausea, renal insufficiency, CD4 suppression, and delayed herpes zoster. Pentostatin is an active agent in this group of diseases and merits further exploration.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Agranulocytosis / chemically induced
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antibiotics, Antineoplastic / therapeutic use*
-
CD4-Positive T-Lymphocytes / drug effects
-
Female
-
Herpes Zoster / etiology
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use*
-
Injections, Intravenous
-
Lymphoma, T-Cell / drug therapy*
-
Lymphoma, T-Cell, Cutaneous / drug therapy
-
Lymphoma, T-Cell, Peripheral / drug therapy
-
Male
-
Middle Aged
-
Nausea / chemically induced
-
Pentostatin / administration & dosage
-
Pentostatin / adverse effects
-
Pentostatin / therapeutic use*
-
Remission Induction
-
Renal Insufficiency / chemically induced
-
Skin Neoplasms / drug therapy
Substances
-
Antibiotics, Antineoplastic
-
Immunosuppressive Agents
-
Pentostatin